Fig. 4

Evaluation of intranasal LaAg efficacy in the progressive stage of infection. C57Bl/6-UFF mice received 10 μg of LaAg by the intranasal route on days -14 and -7 of infection. Non-vaccinated controls received PBS alone. On day 0, animals were infected with 5 × 10⁵ promastigotes of L. amazonensis (Josefa strain). a Lesion sizes were measured at the indicated days and expressed as the difference of thickness between non-infected and infected footpads. b Parasite load was measured on day 44 of infection and expressed as the mean number of parasites. The data (means ± standard deviations; n = 5) are representative of three independent experiments producing the same result profile. P ≤ 0.01 in comparison to PBS controls as follows: a Day 39 (t ₍₇₎ = 3.566, P = 0.0073); Day 44 (t ₍₇₎ = 5.037, P = 0.0015). b t ₍₇₎ = 4.614, P = 0.0024